Phase 2 study for people with Lymphoma

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 15 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 2
Sponsor Merck Sharp & Dohme LLC
Registry number NCT07519772
Started 3 May 2026 Today 16 October 2026 Estimated completion 1 July 2030

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Townsville University Hospital ( Site 0204) Townsville QLD Recruiting
Box Hill Hospital ( Site 0202) Box Hill VIC Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 280

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Has disease that has relapsed (disease progression after remission) or is refractory (failure to achieve complete or partial response) to at least 2 prior systemic lines of therapy.

* Has a histologically confirmed diagnosis of follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL).

* DLBCL participants only: has progressed after or is ineligible for transplant and chimeric antigen receptor T (cell) (CAR-T) therapy.

* Has provided tumor tissue sample (archival or newly obtained, if performed per standard of care).

* Has documented retained expression of cluster of differentiation 19 (CD19) in tumor tissue obtained by biopsy after disease progression on CD19-targeting therapy, if experienced disease progression after prior CD19-targeting therapy.

* Has well-controlled human immunodeficiency virus (HIV) on antiretroviral therapy if has a history of HIV infection.

* Has undetectable hepatitis B virus (HBV) viral load and received and will continue to receive HBV antiviral therapy if hepatitis B surface antigen (HBsAg)-positive.

* Has undetectable hepatitis C virus (HCV) viral load and received HCV antiviral therapy if has a history of HCV infection.

* Has radiographically measurable disease per Lugano Response Criteria.

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has received a solid organ transplant.

* Had or has clinically relevant central nervous system (CNS) diseases.

* Has a history of serious cardiovascular or cerebrovascular diseases.

* Had prior allogenic stem cell transplantation with acute graft-versus-host-disease (GVHD); has ongoing evidence of chronic GVHD manifesting as skin involvement, diarrhea, or increased serum bilirubin; or requires systemic immunosuppression for GVHD.

* Is HIV-infected with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.

* Has received a live or live-attenuated vaccine within 30 days of randomization.

* Has received prior CAR-T therapy within 3 months before the first dose of the study intervention.

* Has a known additional malignancy that is progressing or required active treatment within the past 2 years.

* Has known active CNS lymphoma or involvement.

* Has active autoimmune disease that required systemic treatment in the past 2 years.

* Has active infection requiring systemic therapy.

* Has a history of severe bleeding disorders.

* Has not recovered from major surgery or has ongoing surgical complications.

* Has diagnosis of primary mediastinal B-cell lymphoma.

Dates on the record

Started 3 May 2026
Estimated completion 1 July 2030
Registry last updated 15 October 2026
Checked by Voxsanity 15 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 15 October 2026.
  • This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.